Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic plus systemic corticosteroids (combined therapy) showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids alone (low certainty).
2 findings from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes proportion of patients whose hearing is improved compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes final hearing threshold determined by PTA A lower value represents… compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Persistent tympanic membrane perforation · sudden sensorineural hearing loss
2 findings from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Ear pain: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Histological improvement (continuous) · inactive EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review